jump to content jump to footer

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Research with mint mintLesion Clinical Research Standardized Reading Procedures iRECIST RECIST

Related Resources

Lung Cancer Screening in Germany – A Turning Point for Early Detection
Few topics are currently as impactful in radiology as lung cancer screening. From 2026, Germany is expected to roll out a nationwide program, marking…
Leave No Data Behind: Commitment to Data Excellence
At Mint Medical, we understand data as a cornerstone for improving patient care and groundbreaking research. Our mission is clear: Leave No Data…
Transform Your Research with the Template Designer
At Mint Medical, we know that organized and high-quality data is the foundation of successful research. That's why we've developed the Template…